EHS
EHS

Positive Phase 3 Results for Rimegepant in Acute Migraine

The oral calcitonin gene-related peptide (CGRP) rimegepant performed well compared with placebo for treatment of a single acute migraine attack in a double-blind, randomized phase 3 trial.
Medscape Medical News
EHS
Back to top button